Bridger Management, LLC Biomarin Pharmaceutical Inc Transaction History

Bridger Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $47,379 - $63,325	540 Added 0.38%	142,979 $13.9 Million
Q4 2022 Feb 15, 2023	BUY	$80.93 - $108.63 $3.4 Million - $4.57 Million	42,039 Added 41.87%	142,439 $14.7 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $8.82 Million - $10.4 Million	-107,400 Reduced 51.68%	100,400 $8.51 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $14.9 Million - $18 Million	207,800 New	207,800 $17.2 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridger Management, LLC with notifications on news.